Article

Benign metastasizing leiomyoma: ‘a sheep in wolf’s clothing’


 

Benign metastasizing leiomyoma (BML) is a rare entity,1-9 of which a small number of cases, about 751,4,6 to 120,8-10 have been described in the literature since the condition was first described in 1939. It usually affects women of reproductive age with a history of uterine leiomyomatosis who have undergone a hysterectomy.3,6 The lung is the most common site of involvement.1-4,7-9 The pathologic features of this entity are described as having originated from the metastasis of the histologically benign uterine leiomyoma and are an uncommon lesion characterized by the presence of multiple smooth-muscle nodules that are often located in the lung, lymph nodes, or abdomen.2 Although these lesions are slow growing and asymptomatic and are usually incidentally diagnosed, they may rarely cause debilitating symptoms.1,6 Optimal treatment is controversial, but careful follow-up of these patients is recommended because the lesions show a low-grade clinical malignant behavior although their appearance is benign.4 We describe here a rare case of pulmonary BML ...

*Click on the link to the left for a PDF of the full article.

Recommended Reading

Immunotherapy boosts response in recurrent ovarian cancer
MDedge Hematology and Oncology
Racial genetic admixture linked to endometrial cancer outcomes
MDedge Hematology and Oncology
Cyberknife therapy offers benefits for recurring gyn cancers
MDedge Hematology and Oncology
CA125 level predicts microscopic residual disease in ovarian cancer
MDedge Hematology and Oncology
Retroperitoneal exploration extends survival in stage IIIc ovarian cancer
MDedge Hematology and Oncology
Photodynamic therapy looks promising in early CIN
MDedge Hematology and Oncology
Intraperitoneal chemo superior in low-volume residual ovarian cancer
MDedge Hematology and Oncology
Timely palliative consult affects end-of-life care in gynecologic cancer patients
MDedge Hematology and Oncology
Genetic profiles more clearly defined in endometrial cancer, AML
MDedge Hematology and Oncology
Routine bilateral salpingectomy with hysterectomy gains acceptance
MDedge Hematology and Oncology